Global rise of metabolic fatty liver disease

Medical research and clinical observations indicate a rising global impact of metabolic-associated fatty liver disease (MASLD) and its advanced stage, metabolic dysfunction-associated steatohepatitis (MASH). In Argentina, metabolic liver diseases have surpassed alcohol consumption as the primary cause of cirrhosis, with experts describing the trend as a ‘silent epidemic’ due to the lack of early symptoms.

Clinical data suggests a high prevalence among specific populations, with reports indicating that 70% of overweight individuals and 90% of diabetic patients suffer from fatty liver. In Turkey, high obesity rates—estimated at approximately 32%—have heightened concerns regarding the progression from simple fat accumulation to chronic hepatitis, fibrosis, and liver cancer.

While the condition can lead to severe complications like portal hypertension and liver hardening, experts note that the damage may be reversible. Research suggests that unless advanced cirrhosis has already developed, the condition can be managed through lifestyle changes, such as improved nutrition and regular exercise to address insulin resistance.